Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir + sofosbuvir for hospitalized adults with severe COVID-19
IRCT20200816048422N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of daclatasvir and sofosbuvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Clinical improvement within 14 days, Fever normalization and 2 more. Started Jun 2020; status: completed.
02
Drugs
daclatasvirsofosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200816048422N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200816048422N1.